Entacapone improves the pharmacokinetic and therapeutic response of controlled release levodopa/carbidopa in Parkinson's patients

F. Stocchi, L. Barbato, G. Nordera, A. Bolner, T. Caraceni

Research output: Contribution to journalArticle

Abstract

The aim of this trial was to evaluate the effects of the COMT inhibitor entacapone on both the pharmacokinetic profile and clinical efficacy of controlled release levodopa in Parkinson's disease (PD) patients. Twelve PD patients experiencing 'end-of-dose' type motor fluctuations were evaluated in this single-blind, randomized cross-over study. A single dose of either entacapone (200 mg) or placebo was co-administered with controlled release levodopa. Blood samples were taken every 30 minutes for 3 hours, and in 6 patients, sampling was continued for a further 3 hours. The clinical response to treatment was evaluated using the Unified Parkinson's Disease Rating Scale motor score. Addition of entacapone to levodopa treatment prolonged the 'on' phase of the PD patients by 37% (p

Original languageEnglish
Pages (from-to)173-180
Number of pages8
JournalJournal of Neural Transmission
Volume111
Issue number2
DOIs
Publication statusPublished - Feb 2004

Keywords

  • Controlled release levodopa
  • Entacapone
  • Parkinson's disease

ASJC Scopus subject areas

  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Entacapone improves the pharmacokinetic and therapeutic response of controlled release levodopa/carbidopa in Parkinson's patients'. Together they form a unique fingerprint.

  • Cite this